Tocilizumab biosimilar - GENERIUM Pharmaceuticals
Alternative Names: Complarate; GNR 087Latest Information Update: 16 Jul 2024
At a glance
- Originator GENERIUM Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
Most Recent Events
- 20 Jun 2024 Generium Pharmaceuticals initiates a phase I trial (In volunteers) in Russia (SC) (NCT06488521)
- 05 Jan 2024 GENERIUM pharmaceuticals completes a phase-III clinical trial in Rheumatoid arthritis in Russia (IV) (NCT06475508)